Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes

Drug Review Profile: Inflectra sponsor submitted nonproprietary name suffixes that were both devoid of meaning and meaningful; agency concluded nonmeaningful suffix "-dyyb" was unlikely to be source of error.